MCID: ORP003
MIFTS: 51

Oropharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Oropharynx Cancer

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer 12 15
Oropharyngeal Cancer 12 37 55
Malignant Neoplasm of Oropharynx 12 73
Oropharyngeal Carcinoma 12 73
Primary Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Neoplasm of Junctional Region of Oropharynx 12
Malignant Neoplasm of Posterior Wall of Oropharynx 12
Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Tumor of Posterior Wall of Oropharynx 12
Malignant Tumour of Mesopharynx 12
Malignant Oropharyngeal Tumor 12
Malignant Tumor of Oropharynx 12

Classifications:



Summaries for Oropharynx Cancer

Disease Ontology : 12 A pharynx cancer that is located in the oropharynx.

MalaCards based summary : Oropharynx Cancer, also known as oropharyngeal cancer, is related to oropharyngeal cancer, adult and oropharyngeal cancer, childhood. An important gene associated with Oropharynx Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Pyrimidine metabolism and Glioblastoma Multiforme. The drugs Ethanol and Menthol have been mentioned in the context of this disorder. Affiliated tissues include the oropharynx, lung and tongue, and related phenotypes are homeostasis/metabolism and neoplasm

Wikipedia : 76 Oropharyngeal cancer is a disease in which cancer form in the tissues of the throat (oropharynx). The... more...

Related Diseases for Oropharynx Cancer

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 oropharyngeal cancer, adult 12.0
2 oropharyngeal cancer, childhood 12.0
3 cutaneous telangiectasia and cancer syndrome, familial 11.7
4 tonsil cancer 10.8 CD6 CDKN2A
5 brain stem astrocytic neoplasm 10.8 CDKN2A TP53
6 keratinizing squamous cell carcinoma 10.7 CDKN2A TP53
7 spitz nevus 10.7 CDKN2A TP53
8 bladder carcinoma in situ 10.7 CDKN2A TP53
9 bartholin's gland benign neoplasm 10.7 CDKN2A TP53
10 vulva squamous cell carcinoma 10.7 CDKN2A TP53
11 thyroid lymphoma 10.7 CDKN2A TP53
12 nasal cavity adenocarcinoma 10.7 CDKN2A TP53
13 bone squamous cell carcinoma 10.7 CDKN2A TP53
14 gum cancer 10.7 MMP8 SMUG1
15 anal squamous cell carcinoma 10.7 CDKN2A TP53
16 glycogen-rich clear cell breast carcinoma 10.7 CDKN2A TP53
17 gastric adenosquamous carcinoma 10.7 CDKN2A TP53
18 oral leukoplakia 10.7 CDKN2A TP53
19 megaesophagus 10.7 CDKN2A TP53
20 schneiderian carcinoma 10.7 CDKN2A TP53
21 meningeal melanomatosis 10.7 CDKN2A TP53
22 dedifferentiated liposarcoma 10.7 CDKN2A TP53
23 suppressor of tumorigenicity 3 10.7 CDKN2A TP53
24 endocervical adenocarcinoma 10.6 CDKN2A TP53
25 supraglottis cancer 10.6 CD6 SMUG1
26 gallbladder squamous cell carcinoma 10.6 SMUG1 TP53
27 bartholin's duct cyst 10.6 SMUG1 TP53
28 malignant spiradenoma 10.6 SMUG1 TP53
29 cellular ependymoma 10.6 SMUG1 TP53
30 epidural neoplasm 10.6 CD6 TP53
31 malignant peritoneal mesothelioma 10.6 CDKN2A EGFR
32 cervix small cell carcinoma 10.6 CDKN2A TP53
33 anaplastic oligodendroglioma 10.6 CDKN2A EGFR
34 necrotizing sialometaplasia 10.6 CDKN2A TP53
35 biliary tract neoplasm 10.5 CDKN2A TP53
36 inverted papilloma 10.5 CDKN2A TP53
37 mature teratoma 10.5 SMUG1 TP53
38 pleural cancer 10.5 CDKN2A SMUG1
39 optic nerve neoplasm 10.5 CDKN2A TP53
40 lipid pneumonia 10.5 MMP8 SMUG1
41 cervical adenosquamous carcinoma 10.5 CDKN2A EGFR
42 brain ependymoma 10.5 EGFR TP53
43 tongue cancer 10.4 CDKN2A MMP8 TP53
44 prostate squamous cell carcinoma 10.4 SMUG1 TP53
45 pancreatic ductal carcinoma 10.4 CDKN2A TP53 TYMP
46 cervical squamous cell carcinoma 10.4 CDKN2A TP53 TYMP
47 breast squamous cell carcinoma 10.4 EGFR TP53
48 recessive dystrophic epidermolysis bullosa 10.4 CDKN2A TP53
49 microglandular adenosis 10.4 EGFR TP53
50 pulmonary blastoma 10.4 EGFR TP53

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:



Diseases related to Oropharynx Cancer

Symptoms & Phenotypes for Oropharynx Cancer

MGI Mouse Phenotypes related to Oropharynx Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.65 FAM186B GP6 MMP8 SMUG1 TP53 TYMP
2 neoplasm MP:0002006 9.02 MMP8 SMUG1 TP53 CDKN2A EGFR

Drugs & Therapeutics for Oropharynx Cancer

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 357)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
2
Menthol Approved Phase 4,Phase 2,Not Applicable 2216-51-5 16666
3
Nicotine Approved Phase 4,Phase 2,Phase 3,Not Applicable 54-11-5 942 89594
4
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
5
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
6 sodium fluoride Approved Phase 4 7681-49-4
7 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
13 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
16 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Not Applicable
17 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
19 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
20 Nicotinic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
21 Dopamine Agents Phase 4,Phase 2
22 Dopamine Uptake Inhibitors Phase 4,Phase 2
23 Antidepressive Agents Phase 4,Phase 3,Phase 2
24 Antidepressive Agents, Second-Generation Phase 4,Phase 2
25 Anti-Infective Agents, Local Phase 4,Not Applicable
26 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
27 Fluorides Phase 4,Phase 3,Phase 1,Phase 2
28 Listerine Phase 4
29 Cariostatic Agents Phase 4
30
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
31
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 84093 441203 2767
32
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
33
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
34
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 205923-56-4 56842117 2333
35
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 114977-28-5 148124
36
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
37
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
38
Aldesleukin Approved Phase 3,Phase 2,Phase 1,Not Applicable 85898-30-2, 110942-02-4
39
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
40
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
41
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
42
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5538 5282379
43
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
44
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
45
Fluconazole Approved, Investigational Phase 2, Phase 3,Early Phase 1 86386-73-4 3365
46
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
47
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
48
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
49
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
50
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774

Interventional clinical trials:

(show top 50) (show all 495)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Essential Oils With and Without Alcohol: Substantivity and Antiplaque Effect Recruiting NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
4 Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery Unknown status NCT00181038 Phase 3
5 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
6 Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection Unknown status NCT02268344 Phase 3
7 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
8 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
9 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
10 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
11 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
12 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
13 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
14 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
15 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
16 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
17 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction Completed NCT01018394 Phase 2, Phase 3 nicotine lozenges;tobacco-free snuff
18 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
19 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
21 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
22 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
23 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
24 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
25 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
26 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
27 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
28 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
29 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
30 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
31 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
32 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
33 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
34 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
35 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
36 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
37 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
38 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
39 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
40 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
41 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
42 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
43 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
44 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
45 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
46 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
47 Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Recruiting NCT02908477 Phase 3 Docetaxel;Cisplatin
48 Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma Recruiting NCT01874587 Phase 3
49 Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer Recruiting NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
50 Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck Recruiting NCT01893307 Phase 2, Phase 3

Search NIH Clinical Center for Oropharynx Cancer

Genetic Tests for Oropharynx Cancer

Anatomical Context for Oropharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Oropharynx Cancer:

19
The Oropharynx

MalaCards organs/tissues related to Oropharynx Cancer:

41
Lung, Tongue, Tonsil, Liver, Brain, Lymph Node, Skin

Publications for Oropharynx Cancer

Articles related to Oropharynx Cancer:

(show top 50) (show all 146)
# Title Authors Year
1
Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. ( 29100700 )
2018
2
Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base. ( 29243245 )
2018
3
Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. ( 29969771 )
2018
4
Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. ( 29948260 )
2018
5
Bayesian model and spatial analysis of oral and oropharynx cancer mortality in Minas Gerais, Brazil. ( 29267820 )
2018
6
Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial. ( 29496037 )
2018
7
Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. ( 29961581 )
2018
8
Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer - A retrospective dosimetry review and feasibility planning study. ( 29290281 )
2018
9
HPV status, like politics, is local-evaluating p16 staining and a new staging system in a Dutch cohort of oropharynx cancer. ( 29788169 )
2018
10
Inadequate target volume delineation and local-regional recurrence after intensity-modulated radiotherapy for human papillomavirus-positive oropharynx cancer. ( 28511960 )
2017
11
A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers. ( 28733453 )
2017
12
Analysis of risk factors for oral cavity and oropharynx cancer in the authors' own material. ( 28485297 )
2017
13
Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: AA systematic review. ( 28654785 )
2017
14
Critical Weight Loss in Patients With Oropharynx Cancer During Radiotherapy (A+ Chemotherapy). ( 29083238 )
2017
15
Clinical predictors for reactive tube feeding in patients with advanced oropharynx cancer receiving radiotherapyA A+A chemotherapy. ( 28748260 )
2017
16
Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. ( 28733053 )
2017
17
Prognostic value of ALDH2 polymorphism for patients with oropharyngeal cancer in a Japanese population. ( 29206831 )
2017
18
Marital status as a predictor of survival in patients with human papilloma virus-positive oropharyngeal cancer. ( 28947344 )
2017
19
Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study. ( 28829763 )
2017
20
Beware of deintensification of radiation therapy in patients with p16-positive oropharynx cancer and rheumatological diseases. ( 28242189 )
2017
21
Genetic Mutation and Exosome Signature of Human Papilloma Virus Associated Oropharyngeal Cancer. ( 28383029 )
2017
22
Symptom burden and dysphagia associated with osteoradionecrosis in long-term oropharynx cancer survivors: A cohort analysis. ( 28249651 )
2017
23
A matched comparison of human papillomavirus-induced squamous cancer of unknown primary with early oropharynx cancer. ( 29086413 )
2017
24
The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. ( 28356201 )
2017
25
Risk factors for oropharynx cancer in a cohort of HIV-infected veterans. ( 28438295 )
2017
26
p16(INK4) expression is of prognostic and predictive value in oropharyngeal cancers independent of human papillomavirus status: a Hungarian study. ( 27999998 )
2017
27
Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer. ( 28712533 )
2017
28
Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer. ( 27793210 )
2016
29
Contribution of submandibular gland and swallowing structure sparing to post-radiation therapy PEG dependence in oropharynx cancer patients treated with split-neck IMRT technique. ( 27846899 )
2016
30
Depression and Oropharynx Cancer Outcome. ( 26632757 )
2016
31
Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. ( 27342249 )
2016
32
Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation. ( 27346612 )
2016
33
HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. ( 27569214 )
2016
34
Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. ( 27478170 )
2016
35
Readmission following primary surgery for larynx and oropharynx cancer in the elderly. ( 27659029 )
2016
36
Human Papillomavirus 16 Physical Status and the TP53 Codon 72 Polymorphism in Japanese HPV-Positive Oropharyngeal Cancer Patients. ( 26785263 )
2016
37
Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. ( 26867589 )
2016
38
No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression. ( 26059208 )
2016
39
Clinical results of definitive intensity-modulated radiation therapy for oropharyngeal cancer: retrospective analysis of treatment efficacy and safety. ( 26496935 )
2016
40
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status. ( 27083677 )
2016
41
How does radiotherapy impact swallowing function in nasopharynx and oropharynx cancer? Short-term results of a prospective study. ( 27070541 )
2016
42
Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design. ( 27438230 )
2016
43
A functional variant at miRNA-122 binding site in IL-1a 3' UTR predicts risk of recurrence in patients with oropharyngeal cancer. ( 27121322 )
2016
44
Human papillomavirus genotype and oropharynx cancer survival in the United States of America. ( 26602016 )
2015
45
Leptin receptor expression and Gln223Arg polymorphism as prognostic markers in oral and oropharyngeal cancer. ( 26634459 )
2015
46
Different strokes for different folks: new paradigms for staging oropharynx cancer. ( 25667276 )
2015
47
The negative regulators of Wnt pathway-DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survival. ( 25487617 )
2015
48
A videofluoroscopic study comparing severe swallowing disorders in patients treated surgically or with radiation for oropharyngeal cancer. ( 25697064 )
2015
49
Transoral Endoscopic Head and Neck Surgery and Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials. ( 26351337 )
2015
50
Changing Paradigms for Oropharynx Cancer: Swinging of Pendulum Back Towards Surgery. ( 26349345 )
2015

Variations for Oropharynx Cancer

Expression for Oropharynx Cancer

Search GEO for disease gene expression data for Oropharynx Cancer.

Pathways for Oropharynx Cancer

GO Terms for Oropharynx Cancer

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.62 CDKN2A TP53

Sources for Oropharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....